Lever
Lifestyle
- Regular cardiovascular exercise
- Weight management
- Smoking cessation
Blutwerte · Marker
NT-proBNP
N-terminal pro-BNP · NT-pro-B-type Natriuretic Peptide · BNP
Herzmarker
- Einheit:
- pg/mL
NT-proBNP quantifies the level of N-terminal pro-B-type natriuretic peptide, a marker of cardiac stress and heart failure.
Reference Ranges
Reference
0–125pg/mL
0
125
LowNormalHigh
Reference
Unit · pg/mLReference ranges may vary with age and renal function.
Overview
Übersicht
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a non-active prohormone released from the heart in response to changes in pressure that occur when heart failure develops or worsens. It is a fragment of the precursor to B-type natriuretic peptide (BNP), which plays a role in cardiovascular homeostasis by promoting vasodilation and natriuresis. Researchers have found NT-proBNP to be a valuable biomarker in diagnosing and managing heart failure, particularly in distinguishing between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Elevated levels of NT-proBNP are indicative of cardiac stress and are used to assess the severity and prognosis of heart failure. In the context of athletic performance and longevity, NT-proBNP serves as an indicator of cardiac health, with lower levels generally reflecting better cardiovascular function. However, its interpretation can be confounded by factors such as age, renal function, and obesity. Researchers observed that NT-proBNP levels can be influenced by these variables, necessitating careful consideration when evaluating results. Additionally, NT-proBNP testing does not require fasting and is not significantly affected by the time of day, making it a convenient marker for clinical use.
Klinische Bedeutung
Elevated NT-proBNP levels indicate cardiac stress and are associated with heart failure severity. Low levels are generally indicative of normal cardiac function.
Dynamics
Trend Interpretation
Rising Values
Progressively rising NT-proBNP values suggest worsening heart failure or increased cardiac stress. Re-test in 4 weeks if outside optimal range.
Falling Values
Falling NT-proBNP values suggest improvement in cardiac function or effective treatment of heart failure.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Heart failure
- Renal dysfunction
- Advanced age
- Pulmonary hypertension
- Acute coronary syndrome
Cause
Low Levels
- Normal cardiac function
- Effective heart failure treatment
- Younger age
- Good renal function
Protocol
How to Optimize
Lever
Nutrition
- Low-sodium diet
- Rich in fruits and vegetables
- Adequate hydration
Note:
Consult a healthcare provider for personalized advice, especially if underlying heart conditions exist.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for individuals with risk factors for heart failure, more frequently if symptomatic.
Interfering Factors
- Renal impairment
- Obesity
- Age
Related Peptides & Hormones
Bnp
hormone or peptideDirectly measures
Open Research Questions
Current research suggests that the diagnostic specificity of NT-proBNP in differentiating heart failure with preserved ejection fraction (HFpEF) from reduced ejection fraction (HFrEF) remains debated, particularly due to confounding factors like age and renal function. Researchers have not yet established optimal reference ranges for NT-proBNP in diverse populations, nor clarified its role in conditions like bronchiolitis. Unanswered clinical questions include the integration of NT-proBNP with emerging biomarkers for improved heart failure phenotyping.
52 Research Publications
369
Total Citations
24
Human/RCT
1.8
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
N-Terminal B-type Natriuretic Peptide in Heart Failure.
ReviewInfluence1.0
59
This study focused on the use of NT-proBNP as a biomarker in heart failure (HF). Researchers found that NT-proBNP is effective in diagnosing acute decompensated HF and provides prognostic information independent of standard clinical predictors. It remains the preferred marker for assessing cardiac status in patients receiving ARNI treatment.
02Top
#02
Evidence based application of BNP/NT-proBNP testing in heart failure.
ReviewInfluence2.0
50
This review summarized evidence on the application of BNP and NT-proBNP testing in heart failure. Researchers highlighted the importance of these biomarkers in diagnosing heart failure and discussed their potential roles in prognosis and therapy guidance.
03Top
#03
NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.
Meta-AnalysisInfluence6.0
34
Researchers conducted a systematic review to evaluate NT-proBNP levels in COPD patients. They found that NT-proBNP levels were significantly higher in patients with acute exacerbations and those with severe COPD, indicating its potential role in assessing cardiovascular stress.
04
#04
Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis.
Meta-AnalysisInfluence2.0
33
This meta-analysis compared the diagnostic efficacy of BNP and NT-proBNP in detecting cardioembolic stroke. Researchers found that while BNP showed superior sensitivity, NT-proBNP demonstrated higher specificity in distinguishing cardioembolic from non-cardioembolic strokes.
05
#05
N-terminal-pro-B-type natriuretic peptide (NT-proBNP): reference range for Chinese apparently healthy people and clinical performance in Chinese elderly patients with heart failure.
HumanInfluence1.0
25
This study established reference ranges for NT-proBNP in Chinese individuals and evaluated its clinical performance in diagnosing heart failure. Researchers found that NT-proBNP levels correlate well with heart failure severity but have lower reference ranges compared to Western populations.
06
#06
New issues on measurement of B-type natriuretic peptides.
Review
24
This review discussed the analytical challenges in measuring BNP and NT-proBNP. Researchers highlighted the advantages of NT-proBNP assays for clinical interpretation, suggesting that both biomarkers provide complementary information for managing heart failure patients.
07
#07
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
ReviewInfluence1.0
20
This review discussed the effects of angiotensin receptor-neprilysin inhibitor (ARNI) therapy on the natriuretic peptide axis, including NT-proBNP. Researchers found that ARNI therapy decreases NT-proBNP levels while improving echocardiographic parameters, suggesting a link between NT-proBNP changes and cardiac function.
08
#08
Biomarkers in Takayasu arteritis.
Wen Dan, et al. · International journal of cardiology · 2023
Review
18
This study examined the role of various biomarkers, including NT-proBNP, in Takayasu arteritis (TA), a rare vasculitis affecting major arteries. Researchers found that these biomarkers are valuable for early diagnosis, evaluating disease activity, and guiding treatment options in TA patients.
Key findings
- 01Researchers observed that Takayasu arteritis involves complex interactions between immune system components and inflammation.
- 02They identified several biomarkers, including cytokines and autoantibodies, that may help in understanding the disease.
- 03The study highlights the need for further research to clarify the role of these biomarkers in Takayasu arteritis.
09
#09
How to use N-terminal pro-brain natriuretic peptide (NT-proBNP) in assessing disease severity in bronchiolitis.
ReviewInfluence1.0
18
Researchers investigated the use of NT-proBNP as a biomarker for assessing severity in bronchiolitis. They found that elevated NT-proBNP levels can differentiate between cardiac and respiratory causes of distress in children, indicating its potential utility in clinical settings.
10
#10
NT-proBNP: When is it useful in Obstetric Medicine?
Review
17
Researchers examined the role of NT-proBNP in obstetric medicine, particularly in identifying cardiac issues during pregnancy. They found that elevated NT-proBNP levels can indicate increased cardiac filling pressures and assist in diagnosing conditions like peripartum cardiomyopathy.
Clinical Trials (18)
18
Total Trials
5,108
Total Enrolled
Bedside NT-proBNP Monitoring in Acute Heart Failure
NCT07762521NOT_YET_RECRUITING
Sponsor
Mao Chen
Enrollment
50
Started
2026
Primary outcome
Percentage Change in NT-proBNP Levels From Baseline During Hospitalization
Acute Decompensated Heart Failure (ADHF)
Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure
NCT07460505NOT_YET_RECRUITING
Sponsor
National University Hospital, Singapore
Enrollment
328
Started
2026
Primary outcome
N-terminal pro-B-type natriuretic peptide (NT-pro BNP)
Heart FailureOSA - Obstructive Sleep Apnea
The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.
Sponsor
Ziekenhuis Oost-Limburg
Enrollment
100
Started
2026
Primary outcome
Time to first occurrence of recurrent adverse remodeling, significant NT-proBNP increase or all-cause mortality.
Heart Failure
Early Diagnosis of Heart Failure Using NT-proBNP Levels in Primary Care
NCT07059260NOT_YET_RECRUITING
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Enrollment
304
Started
2025
Primary outcome
Clinical benefit based on a hierarchical composite outcome (win ratio approach)
Heart Failure
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
NCT06593327RECRUITING
Sponsor
University of Texas Southwestern Medical Center
Enrollment
300
Started
2025
Primary outcome
Incident Heart Failure or All-cause death
Type 2 DiabetesDiabetic CardiomyopathyHeart FailureCardiometabolic Diseases
SGLT2 for Heart Failure in CHD Patients
NCT05897489UNKNOWN
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
100
Started
2023
Primary outcome
To evaluate, on real-life data, the efficacy of iSGLT2 in patients with heart failure related to congenital heart disease as defined by improvement in NYHA class and/or change in NT-proBNP.
Heart Failure
Secondary Use of PARALLEL-HF Data
NCT07527767COMPLETED
Sponsor
Novartis Pharmaceuticals
Enrollment
236
Started
2022
Primary outcome
association between change in NYHA classification and change in plasma log BNP levels from Baseline
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Perioperative Troponin I and NT Pro-BNP in Lung Resection
NCT04749212COMPLETED
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Enrollment
475
Started
2021
Primary outcome
NT-proBNP perioperative changes
Cardiac IschemiaThoracic CancerComplication,Postoperative
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
Sponsor
M.D. Anderson Cancer Center
Enrollment
79
Started
2021
Primary outcome
Percent Change in NTproBNP at 6 Months Visit From Baseline
Locally Advanced Neuroendocrine NeoplasmMetastatic Neuroendocrine Neoplasm
NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study
NCT04125966UNKNOWN
Sponsor
University of Aarhus
Enrollment
403
Started
2019
Primary outcome
Diagnostic performance of NT-proBNP for ruling out heart failure in atrial fibrillation patients
Atrial FibrillationHeart Failure
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Sponsor
Eidos Therapeutics, a BridgeBio company
Enrollment
632
Started
2019
Primary outcome
A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.
AmyloidosisAmyloid CardiomyopathyTransthyretin AmyloidosisCardiomyopathiesHeart Diseases
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
Sponsor
Morten Schou
Enrollment
190
Started
2017
Primary outcome
Between-group difference in the change of plasma concentrations of NT-proBNP
Heart Failure With Reduced Ejection Fraction
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
Sponsor
Novartis Pharmaceuticals
Enrollment
794
Started
2016
Primary outcome
Change in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to One Year
Heart Failure
NT-proBNP in the Management of Discharged Patients With Acutely Decompensated Heart Failure and Preserved Ejection Fraction
NCT02807168COMPLETED
Sponsor
Hospital Universitario Virgen de la Arrixaca
Enrollment
167
Started
2015
Primary outcome
Decrease of rehospitalizations due to acute heart failure at 6 months after discharge.
Heart FailurePreserved Left Ventricular Ejection Fraction
Urine NT-ProBNP in Neonatal Respiratory Distress
NCT02020993UNKNOWN
Sponsor
Ankara University
Enrollment
150
Started
2013
Primary outcome
severity of respiratory distress
Neonatal Respiratory Distress
Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?
NCT00586027COMPLETED
Sponsor
Klinikum Ludwigshafen
Enrollment
150
Started
2008
Primary outcome
The primary objective is to monitor NT-proBNP for 7 days in patients with an intraoperative low cardiac output. Cardiac index and NT-proBNP will be correlated with morbidity and mortality.
Cardiac SurgeryLow Cardiac OutputNatriuretic Peptide B
Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients
Sponsor
Medical University of Vienna
Enrollment
300
Started
2007
Primary outcome
Reduction in cardiac events
Diabetes MellitusHeart FailureCoronary Artery Disease
Serial Measurements of Biomarker in Patients With Acute Decompensated Heart Failure
NCT00514384COMPLETED
Sponsor
University Hospital, Basel, Switzerland
Enrollment
350
Started
2007
Primary outcome
Course of BNP, NT-proBNP, MR-proADM, Copeptin, ST2, hsTnT
Acute Heart Failure
Publication Trend
Research publications about NT-proBNP over time
8totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer